Paper Details

  1. Home
  2. Paper Details

Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial.

Author: AugustinAlbert J, BentzJuergen, DiehmCurt, GriegerFrank

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Intravenous alprostadil infusion showed a numerical treatment effect in favor of alprostadil in patients with dry age-related macular degeneration (dAMD), which lasted until the end of follow-up. This suggests that alprostadil may have a therapeutic effect in the treatment of dAMD and justifies further clinical studies.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJEC...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/13543784.2013.794782

データ提供：米国国立医学図書館（NLM）

Alprostadil Infusion: A New Approach to Treating Dry Age-Related Macular Degeneration

Dry age-related macular degeneration (dAMD) is a leading cause of blindness in elderly individuals, and new treatment options are desperately needed. This study investigates the potential of [alprostadil], a prostaglandin E1, as a treatment for dAMD. The study was a [randomized controlled clinical trial] that compared intravenous infusions of alprostadil to a placebo in patients with dAMD. Results showed a numerical improvement in best corrected visual acuity (BCVA) in the alprostadil group compared to the placebo group, indicating a potential therapeutic benefit. The study emphasizes the need for further research to validate these findings and evaluate the long-term efficacy and safety of alprostadil for dAMD.

Hope on the Horizon for Dry AMD

This research offers a ray of hope for individuals struggling with dAMD. The study's findings suggest that alprostadil may have therapeutic potential for this debilitating condition. While further research is needed to confirm these findings and establish the optimal dosage and treatment duration, this research offers a promising avenue for developing new treatment options for dAMD.

Protecting Vision: The Importance of Early Detection

This research highlights the importance of early detection and treatment for dAMD. Regular eye exams are crucial for identifying early signs of the disease and ensuring prompt intervention. Lifestyle modifications such as a healthy diet, regular exercise, and smoking cessation can also play a role in reducing the risk of developing dAMD.

Dr.Camel's Conclusion

This study suggests that alprostadil infusion may be a promising treatment for dry age-related macular degeneration, offering hope for individuals seeking new therapeutic options. Further research is needed to validate these findings and establish the optimal dosage and treatment duration. As Dr. Camel, I am encouraged by this potential new treatment and believe that it could lead to better outcomes for individuals with dAMD.

Date :
  1. Date Completed 2014-01-17
  2. Date Revised 2013-06-17
Further Info :

Pubmed ID

23627650

DOI: Digital Object Identifier

10.1517/13543784.2013.794782

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.